Jacob Gottlieb thinks OHR Pharmaceutical Inc (NASDAQ:OHRP) is a good investment and has initiated a new position for his fund, Visium Asset Management. According to a recent filing with the Securities and Exchange Commission, Gottlieb and Visium have acquired 1.22 million shares, amassing 5.2% of the company’s common stock.
Both Cliff Asness and Israel Englander have become fans of OHR Pharmaceutical Inc (NASDAQ:OHRP) and have initiated positions for their respective funds. Englander’s Millennium Management has acquired a little over 900,000 shares during the first quarter of 2014, as reported in the fund’s latest 13F filing. The position built by Asness during the same period for AQR Capital Management is much smaller – 13,100 shares. Geoffrey Raynor is also bullish on OHR Pharmaceutical Inc (NASDAQ:OHRP) and has acquired approximately 57,600 shares for his fund, Q Investments (Specter Holdings), according to its latest 13F filing.